Contrast agents are used in Magnetic Resonance Imaging (MRI) in order to enhance target tissues and make them easier to evaluate. Gadolinium based contrast agents (GBCAs) are the most widely used and are cleared by the kidneys soon after injection. This mechanism of excretion poses an issue for patients with renal insufficiency as the excretion time increases significantly. This delay gives the contrast agent time to break down before it is cleared by the patients’ kidneys. As a result, unbound gadolinium deposition in the body, including in the brain, has been reported. This deposition can result in Nephrogenic Systemic Fibrosis (NSF), a progressive multiorgan fibrosing condition. Ferumoxytol is a potential alternative contrast agent that is cleared by the reticuloendothelial system. It is an ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle coated with a low molecular weight semi-synthetic carbohydrate. Ferumoxytol has been used as an IV treatment for iron deficiency for over a decade but due to its biocompatibility, biodegradability, and strong magnetism, it has also been used off label as an MR contrast agent. Ferumoxytol has several benefits over GBCAs including no risk of NSF due to its biodegradability and no errors resulting from contrast dynamics and dilution due to its uniform distribution throughout the entire blood pool. Additionally, ferumoxytol’s much longer half-life (>15 hours) supports an increase in the potential applications. Ferumoxytol even has potential for tumor treatment via hyperthermia on cancer tissue under an external magnetic field. Lastly, uptake by macrophages has potential applications in detecting and monitoring inflammatory conditions. Ferumoxytol uptake has been shown in the liver and spleen (members of the reticuloendothelial system) and unexpectedly the adrenal glands. There is not currently a clear understanding of why adrenal uptake occurs, so this project aims to explain the mechanism of adrenal uptake by analyzing MR images of patients with pancreatic adenocarcinoma at the time of ferumoxytol injection and 24 hours after injection. Additionally, this uptake will be compared with the iron deposition in the adrenals of patients receiving blood transfusions or iron infusions due to Beta Thalassemia or other disorders resulting in anemia. Understanding more about the deposition of ferumoxytol in the adrenals is a crucial step in ensuring that the use of ferumoxytol as a contrast agent is safe. Lastly, MR detection of such ferumoxytol uptake in the adrenals could prove to be a lifesaving tool for early detection of lung cancer metastasis to the adrenal glands.